Dazodalibep Shows Phase 3 Benefit in Sjögren Disease

Amgen's dazodalibep showed significant reduction in systemic disease activity in Sjögren's patients in a phase 3 trial, with both dosing regimens outperforming placebo. The every-4-weeks regimen also improved patient-reported dryness. Common side effects were mild to moderate. Amgen is conducting further trials. According to the company, results support dazodalibep's potential as a first-in-class treatment.

Original reporting
Published Nov 18, 2026, 4:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 19, 2026, 3:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Dazodalibep Shows Phase 3 Benefit in Sjögren Disease — source image
Decision brief

The 30-second read

$AMGNBullishMed
01

Why it matters

The data could position Amgen as a leader in this niche, prompting analyst upgrades.

02

Market read

First‑in‑class Phase 3 success may drive Amgen stock higher and influence the autoimmune biotech sector.

03

What to watch

Regulatory pathway timing and reimbursement landscape could temper upside.

Relevance 8/10Novelty 9/10Timing: today

Background

Sjögren disease lacks approved disease‑modifying therapies; Amgen's dazodalibep is a novel CD40L antagonist.

Company-level read

Ticker impact

$AMGNBullishHigh confidence
Context

Amgen announced positive Phase 3 results for its CD40L antagonist dazodalibep in Sjögren disease, showing significant reduction in disease activity.

Expected impact

likely upward pressure as investors price in a first‑in‑class therapy for an unmet autoimmune market

Evidence & confidence

Phase 3 efficacy and safety data are new, material, and could drive near‑term buying interest.

Market effects

May boost the broader autoimmune‑therapy sector and increase interest in CD40L‑targeted drugs.

U.S. biotech stocks could see modest gains.

Potentially relevant for global investors tracking rare‑disease pipelines.

Counterpoint

Skeptics may question long‑term safety or market uptake given competition in autoimmune space.

Key entities

  • Amgen

    Developer of dazodalibep

  • Dazodalibep

    Investigational CD40L antagonist

Related articles

$GSKMedAI 8/10

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

$AMGNMed

Amgen’s acquired Sjögren's drug a Phase III hit

Amgen's dazodalipeb showed positive results in a Phase III trial for Sjögren’s disease, meeting primary endpoints with significant improvements in disease activity and symptoms. The drug was acquired via Amgen's 2023 takeover of Horizon Pharma. Analysts suggest it may have advantages over competitors like Novartis' ianalumab. Amgen plans to continue Phase III trials. Sjögren’s disease affects around 4 million people in the US.